Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manyi Xu

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|December 29, 2025
Discovery and Optimization of Phenoxazinone Derivatives as Potent Antitubercular Agents Targeting FabD ProteinManyi Xu, Lingling Xu, Bin Wang, et al.
International Journal of Molecular Sciences|May 25, 2024
DDCM: A Computational Strategy for Drug Repositioning Based on Support-Vector Regression AlgorithmManyi Xu, Wan Li, Jiaheng He, et al.
Cancer Investigation|September 16, 2024
Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs)Zheng Shi, Xiaohong Zeng, Wei Sun, et al.
European Journal of Medicinal Chemistry|October 14, 2018
Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activitiesNa Li, Manyi Xu, Na Bao, et al.
Journal of Medicinal Chemistry|March 3, 2022
Discovery of Novel Celastrol-Imidazole Derivatives with Anticancer Activity <i>In Vitro</i> and <i>In Vivo</i>Na Li, Manyi Xu, Lulu Zhang, et al.
International Journal of Clinical Pharmacy|April 26, 2025
Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system databaseZheng Shi, Keda Shao, Ke Wang, et al.
Journal of Applied Microbiology|October 15, 2025
5-Iodotubercidin: a novel anti-tuberculosis lead with promising antimicrobial activity, pharmacokinetics, and safety profileXuelin Wang, Manyi Xu, Lu Wang, et al.
Journal of Medicinal Chemistry|November 15, 2019
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor ActivityNa Li, Manyi Xu, Bing Wang, et al.
Therapeutic Advances in Medical Oncology|May 30, 2024
Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastasesYue Hao, Manyi Xu, Xiaohong Zeng, et al.
Communications Biology|March 31, 2026
Questiomycin A demonstrates antibacterial activity against Mycobacterium tuberculosis by directly targeting FabDLingling Xu, Manyi Xu, Bin Wang, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|December 29, 2025
Discovery and Optimization of Phenoxazinone Derivatives as Potent Antitubercular Agents Targeting FabD ProteinManyi Xu, Lingling Xu, Bin Wang, et al.
International Journal of Molecular Sciences|May 25, 2024
DDCM: A Computational Strategy for Drug Repositioning Based on Support-Vector Regression AlgorithmManyi Xu, Wan Li, Jiaheng He, et al.
Cancer Investigation|September 16, 2024
Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs)Zheng Shi, Xiaohong Zeng, Wei Sun, et al.
European Journal of Medicinal Chemistry|October 14, 2018
Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activitiesNa Li, Manyi Xu, Na Bao, et al.
Journal of Medicinal Chemistry|March 3, 2022
Discovery of Novel Celastrol-Imidazole Derivatives with Anticancer Activity <i>In Vitro</i> and <i>In Vivo</i>Na Li, Manyi Xu, Lulu Zhang, et al.
International Journal of Clinical Pharmacy|April 26, 2025
Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system databaseZheng Shi, Keda Shao, Ke Wang, et al.
Journal of Applied Microbiology|October 15, 2025
5-Iodotubercidin: a novel anti-tuberculosis lead with promising antimicrobial activity, pharmacokinetics, and safety profileXuelin Wang, Manyi Xu, Lu Wang, et al.
Journal of Medicinal Chemistry|November 15, 2019
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor ActivityNa Li, Manyi Xu, Bing Wang, et al.
Therapeutic Advances in Medical Oncology|May 30, 2024
Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastasesYue Hao, Manyi Xu, Xiaohong Zeng, et al.
Communications Biology|March 31, 2026
Questiomycin A demonstrates antibacterial activity against Mycobacterium tuberculosis by directly targeting FabDLingling Xu, Manyi Xu, Bin Wang, et al.
Pageof 5